--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-23-102132" form_type: "8-K" ticker: "ARMP" cik: "0000921114" company_name: "Armata Pharmaceuticals, Inc." filed_at: "2023-09-20T23:59:59+00:00" generated_at: "2026-06-10T12:54:07.238435+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.55 calibrated_materiality_score: 0.55 confidence: "high" source: SEC EDGAR --- # Armata promotes Rychlik to CFO; shareholders approve director elections and stock issuance ## Summary - Richard Rychlik, Corporate Controller since Sept 5, promoted to principal financial officer, replacing Julianne Averill of Danforth Advisors who resigned as CFO. - Shareholders elected seven directors to one-year terms: Deborah Birx, Jules Haimovitz, Odysseas Kostas, Robin Kramer, Joseph Patti, Todd Peterson, Sarah Schlesinger. - Non-binding advisory vote on executive compensation approved: 29,620,537 for, 49,049 against, 14,773 abstentions. - Shareholders ratified Ernst & Young as independent auditor for FY2023: 30,850,478 for, 37,396 against. - Approved issuance of common stock upon conversion of loan from Innoviva Strategic Opportunities LLC under NYSE American rules. ## SEC filing metadata - accession: 0001104659-23-102132 - form_type: 8-K - ticker: ARMP - cik: 0000921114 - company_name: Armata Pharmaceuticals, Inc. - filed_at: 2023-09-20T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.55 - calibrated_materiality_score: 0.55 - confidence: high - sec_items: 5.02, 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465923102132/0001104659-23-102132-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465923102132/tm2326466d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-23-102132 - JSON: https://secwatch.observer/filing/0001104659-23-102132.json - Plain text: https://secwatch.observer/filing/0001104659-23-102132.txt ## Key facts - Executive change Richard Rychlik changed role as principal financial officer at Armata Pharmaceuticals, Inc.. - Action: promoted - Role: principal financial officer source text: On September 15, 2023, Richard Rychlik, Corporate Controller of Armata Pharmaceuticals, Inc. (“Armata” or the “Company”), was promoted to serve as Armata’s principal financial officer evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923102132/0001104659-23-102132-index.htm - Executive change Julianne Averill resigned as Chief Financial Officer at Armata Pharmaceuticals, Inc.. - Action: resigned - Role: Chief Financial Officer source text: Julianne Averill of Danforth Advisors, LLC, who resigned as Chief Financial Officer on the same day. evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923102132/0001104659-23-102132-index.htm - Shareholder Votes Armata Pharmaceuticals, Inc. shareholders approved Election of seven directors to serve for one-year terms expiring at the 2024 annual meeting at the 2023-09-14 meeting. - Proposal: director election - Outcome: passed - Meeting: 2023-09-14 source text: At the Annual Meeting of Shareholders held on September 14, 2023 (the “Meeting”), the shareholders of the Company elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2024, as follows: Members Number of Shares Voted For Number of Shares Withheld Broker Non- Votes Deborah L. Birx, M.D. 29,376,679 307,680 1,204,286 Jules Haimovitz 28,721,661 962,698 1,204,286 Odysseas D. Kostas, M.D. 28,740,184 944,175 1,204,286 Robin C. Kramer 29,478,509 205,850 1,204,286 Joseph M. Patti, Ph. D. 29,478,115 206,244 1,204,286 Todd C. Peterson, Ph. D. 29,483,125 201,234 1,204,286 Sarah Schlesinger, M.D. 28,743,451 940,908 1,204,286 evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923102132/0001104659-23-102132-index.htm - Shareholder Votes Armata Pharmaceuticals, Inc. shareholders approved Non-binding advisory approval of the compensation of the Company's named executive officers at the 2023-09-14 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2023-09-14 source text: At the Meeting, our shareholders next approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The vote for such approval was 29,620,537 shares for, 49,049 shares against, 14,773 shares abstaining, and 1,204,286 shares of broker non-votes. evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923102132/0001104659-23-102132-index.htm - Shareholder Votes Armata Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-09-14 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2023-09-14 source text: Also at the Meeting, our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023. The vote for such ratification was 30,850,478 shares for, 37,396 shares against, 771 shares abstaining, and 0 shares of broker non-votes. evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923102132/0001104659-23-102132-index.htm - Shareholder Votes Armata Pharmaceuticals, Inc. shareholders approved Approval of issuance of common stock upon conversion of loan under secured convertible credit and security agreement with Innoviva Strategic Opportunities LLC at the 2023-09-14 meeting. - Outcome: passed - Meeting: 2023-09-14 source text: Also at the Meeting, our shareholders approved, in accordance with the NYSE American exchange rules, the issuance of our common stock upon conversion, if applicable, of the loan outstanding under our secured convertible credit and security agreement entered into with Innoviva Strategic Opportunities LLC. The vote for such approval was 29,637,787 shares for, 33,901 shares against, 12,671 shares abstaining, and 1,204,286 shares of broker non-votes. evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465923102132/0001104659-23-102132-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.